Predictive marker for response to trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer patients
- Published on 01/09/2025
- Reading time: 4 min.
Takahashi Toshiaki 1, Shigeyasu Kunitoshi 1, Kondo Yoshitaka 1, Takeda Sho 1, Umeda Hibiki 1, Moriwake Kazuya 1, Kayano Masashi 1, Sakurai Yuya 1, Nakamura Shunsuke 1, Takahashi Masafumi 1, Nitta Kaori 1, Yoshida Kazuhiro 1, Matsumi Yuki 1, Michiue Hiroyuki 2, Yamamoto Hideki 3, Kishimoto Hiroyuki 1, Teraishi Fuminori 1, Shoji Ryohei 1, Kanaya Nobuhiko 1, Kashima Hajime 1, Kakiuchi Yoshihiko 1, Kuroda Shinji 1, Kagawa Shunsuke 1, Fujiwara Toshiyoshi 1
1 https://ror.org/02pc6pc55 Department of Gastroenterological Surgery Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences 2-5-1 Shikata-Cho, Kita-Ku 700-8558 Okayama Japan
2 https://ror.org/02pc6pc55 Neutron Therapy Research Center Okayama University Okayama Japan
3 https://ror.org/02pc6pc55 Department of Clinical Genomic Medicine Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences Okayama Japan
Abstract
Objective Trifluridine/tipiracil (FTD/TPI) is one of the options for late-line treatment of colorectal cancer (CRC). However, the specific patient populations that would particularly benefit from it remain unclear. This study attempted to identify predictive markers of chemotherapy efficacy with trifluridine/tipiracil (FTD/TPI), focusing on the RNA-editing enzyme adenosine deaminase acting on RNA 1 (ADAR1) expression and neutrophil–lymphocyte ratio (NLR).
Methods...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Oncology
Receive our newsletter to stay up to date with the latest news in Oncology
